• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by iCAD Inc.

    7/17/25 4:58:43 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care
    Get the next $ICAD alert in real time by email
    S-8 POS 1 icad_s8pos.htm POST EFFECTIVE AMENDMENT TO S-8

    As filed with the Securities and Exchange Commission on July 17, 2025

     

    Registration No. 333-99973

    Registration No. 333-119509

    Registration No. 333-139023

    Registration No. 333-144671

    Registration No. 333-161959

    Registration No. 333-187660

    Registration No. 333-201874

    Registration No. 333-211656

    Registration No. 333-229453

    Registration No. 333-235580

    Registration No. 333-280660

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-99973

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-119509
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-139023

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-144671

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-161959

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-187660
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-201874

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-211656

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-229453

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-235580
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-280660


    UNDER THE SECURITIES ACT OF 1933

     

     

    iCAD, INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of incorporation or organization)

      02-0377419
    (I.R.S. Employer Identification No.)

     

    2 Townsend West

    Suite 6

    Nashua, New Hampshire

    (Address of Principal Executive Offices)

     

    03063

    (Zip Code)

     

     

    iCAD, Inc. 2001 Stock Option Plan

    iCAD, Inc. 2002 Stock Option Plan

    Intelligent Systems Software, Inc. 2001 Stock Option Plan

    Non-Plan Stock Options

    iCAD, Inc. 2004 Stock Incentive Plan

    iCAD, Inc. 2005 Stock Incentive Plan

    Non-Plan Options Granted to Certain Employees

    iCAD, Inc. 2007 Stock Incentive Plan

    iCAD, Inc. 2012 Stock Incentive Plan

    iCAD, Inc. 2012 Stock Incentive Plan, as amended

    iCAD, Inc. 2016 Stock Incentive Plan

    iCAD, Inc. 2016 Stock Incentive Plan as amended

    iCAD, Inc. 2019 Employee Stock Purchase Plan

    iCAD, Inc. 2024 Omnibus Equity Incentive Plan

    (Full title of the plan)

     

     

    Mark D. Stolper

    Chief Financial Officer

    iCAD, Inc.

    2 Townsend West

    Suite 6

    Nashua, New Hampshire 03063

    ((Name and address of agent for service)

     

    (603) 882-5200

    (Telephone number, including area code, of agent for service)

     

     

    With a copy to:

    Andrew Moore

    Jonathan S. Schulman

    Christopher Wassman

    Perkins Coie LLP

    1301 Second Avenue, Suite 4200

    Seattle, Washington 98101

    (206) 359-8000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “small reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer  
    Non-accelerated filer x Smaller reporting company x
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

       

     

     

    DEREGISTRATION OF SECURITIES

     

    These Post-Effective Amendments (the “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (collectively, the “Registration Statements”) filed by iCAD, Inc. (“iCAD” or the “registrant”) with the Securities and Exchange Commission (the “SEC”):

     

    ·Registration Statement No. 333-99973, filed with the SEC on September 20, 2002, registering 3,390,000 shares of iCAD’s common stock, par value $0.01 per share (the “Common Stock”), issuable pursuant to the iCAD, Inc. 2001 Stock Option Plan, the iCAD, Inc. 2002 Stock Option Plan, the Intelligent Systems Software, Inc. 2001 Stock Option Plan and the Non-Plan Stock Options granted to certain officers, directors and employees of iCAD.
    ·Registration Statement No. 333-119509, filed with the SEC on October 4, 2004, registering 1,000,000 shares of Common Stock issuable pursuant to the iCAD, Inc. 2004 Stock Incentive Plan.
    ·Registration Statement No. 333-139023, filed with the SEC on November 30, 2006, registering 2,694,750shares of Common Stock issuable pursuant to the iCAD, Inc. 2005 Stock Incentive Plan and upon exercise of Non-Plan Options Granted to Certain Employees.
    ·Registration Statement No. 333-144671, filed with the SEC on July 18, 2007, registering 2,250,000 shares of Common Stock issuable pursuant to the iCAD, Inc. 2007 Stock Incentive Plan.
    ·Registration Statement No. 333-161959, filed with the SEC on September 16, 2009, registering 3,000,000 shares of Common Stock issuable pursuant to the iCAD, Inc. 2007 Stock Incentive Plan.
    ·Registration Statement No. 333-187660, filed with the SEC on April 1, 2013, registering 600,000 shares of Common Stock issuable pursuant to the iCAD, Inc. 2012 Stock Incentive Plan.
    ·Registration Statement No. 333-201874, filed with the SEC on February 4, 2015, registering 1,245,000 shares of Common Stock issuable pursuant to the iCAD, Inc. 2012 Stock Incentive Plan, as amended by Amendment No. 1.
    ·Registration Statement No. 333-211656, filed with the SEC on May 26, 2016, registering 1,700,000 shares of Common Stock issuable pursuant to the iCAD, Inc. 2016 Stock Incentive Plan.
    ·Registration Statement No. 333-229453, filed with the SEC on January 31, 2019, registering 900,000 shares of Common Stock issuable pursuant to the iCAD, Inc. 2016 Stock Incentive Plan as amended December 2018.
    ·Registration Statement No. 333-235580, filed with the SEC on December 19, 2019, registering 950,000 shares of Common Stock issuable pursuant to the iCAD, Inc. 2019 Employee Stock Purchase Plan.
    ·Registration Statement No. 333-280660, filed with the SEC on July 2, 2024, registering 4,100,000 shares of Common Stock issuable pursuant to the iCAD, Inc. 2024 Omnibus Equity Incentive Plan and the iCAD, Inc. 2016 Stock Incentive Plan, as amended.

     

    The share numbers listed above do not reflect the registrant’s 1-for-5 reverse stock split, effected on August 15, 2012.

     

    On July 17, 2025, pursuant to the Agreement and Plan of Merger, dated April 15, 2025, by and among RadNet, Inc., a Delaware corporation (“RadNet”), Trio Merger Sub, Inc., a wholly-owned subsidiary of RadNet and a Delaware corporation (“Merger Sub”), and iCAD, Merger Sub merged with and into iCAD, with iCAD surviving as a wholly-owned subsidiary of RadNet.

     

    As a result of the transactions contemplated by the Merger Agreement, iCAD has terminated all of the offerings and sales of iCAD’s securities pursuant to the Registration Statements. In accordance with the undertakings made by iCAD in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities of iCAD registered under such Registration Statements which remain unsold at the termination of the offering, iCAD hereby removes from registration, by means of these Post-Effective Amendments, all of the securities of iCAD registered under the Registration Statements that remain unsold as of the date of these Post-Effective Amendments, if any. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and iCAD hereby terminates the effectiveness of each of the Registration Statements.

     

     

     

     2 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Nashua, State of New Hampshire, on the 17th day of July, 2025.

     

      iCAD, Inc.
       
      /s/ Mark D. Stolper
      By: Mark D. Stolper
      Title: Chief Financial Officer

     

    No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     3 

     

    Get the next $ICAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICAD

    DatePrice TargetRatingAnalyst
    4/17/2025Buy → Neutral
    BTIG Research
    4/17/2025Buy → Hold
    Laidlaw
    1/18/2022Buy → Neutral
    Guggenheim
    1/5/2022$22.00 → $16.00Outperform
    Oppenheimer
    11/10/2021$22.00 → $18.00Market Outperform
    JMP Securities
    More analyst ratings

    $ICAD
    SEC Filings

    View All

    SEC Form 15-12G filed by iCAD Inc.

    15-12G - ICAD INC (0000749660) (Filer)

    7/28/25 4:32:12 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by iCAD Inc.

    EFFECT - ICAD INC (0000749660) (Filer)

    7/22/25 12:15:13 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by iCAD Inc.

    EFFECT - ICAD INC (0000749660) (Filer)

    7/22/25 12:15:08 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    $ICAD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. "Scott's extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team," said Dr. Jennifer Bath, MindWalk CEO. "His proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our Bio-Native AI platform globally." Mr. Areglado brings more

    10/21/25 8:28:00 AM ET
    $BWAY
    $HYFT
    $ICAD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    RadNet's Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

    Acquisition contributes iCAD's commercial, technology, and regulatory capabilitiesThe acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutionsThe combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ:ICAD) ("iCAD"), a global lead

    7/17/25 9:00:00 AM ET
    $ICAD
    $RDNT
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    iCAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote "FOR" Proposed Acquisition by RadNet, Inc.

    NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company"), a global leader in clinically proven AI-powered cancer detection solutions, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co. ("Glass Lewis") have each recommended that stockholders vote "FOR" the previously announced acquisition of the Company by RadNet, Inc. ("RadNet") at the Company's upcoming Special Meeting of Stockholders scheduled for July 14, 2025, at 9:00 a.m. ET to be held virtually at www.cstproxy.com/icad/sm2025. As previously announced, iCAD entered into a definitive merger agreement under

    7/8/25 8:00:00 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    $ICAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hricak Hedvig

    4 - ICAD INC (0000749660) (Issuer)

    7/17/25 9:02:06 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    Officer Go Jonathan returned 188,725 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ICAD INC (0000749660) (Issuer)

    7/17/25 9:01:50 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    Director Wood Susan Alyson returned 4,134 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ICAD INC (0000749660) (Issuer)

    7/17/25 9:01:37 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    $ICAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iCAD downgraded by BTIG Research

    BTIG Research downgraded iCAD from Buy to Neutral

    4/17/25 8:29:51 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    iCAD downgraded by Laidlaw

    Laidlaw downgraded iCAD from Buy to Hold

    4/17/25 8:29:51 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    icad downgraded by Guggenheim

    Guggenheim downgraded icad from Buy to Neutral

    1/18/22 7:19:48 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    $ICAD
    Leadership Updates

    Live Leadership Updates

    View All

    MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. "Scott's extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team," said Dr. Jennifer Bath, MindWalk CEO. "His proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our Bio-Native AI platform globally." Mr. Areglado brings more

    10/21/25 8:28:00 AM ET
    $BWAY
    $HYFT
    $ICAD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer

    NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringing with him extensive executive experience in the medical imaging field and software as a medical device (SaMD) space. In his new role, Mark will have oversight of the commercial sales teams, partnersh

    4/8/25 10:19:01 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

    NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Dr. Hricak to its Board of Directors, effective immediately. Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field. For more than 20 years, she was Chair of the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK) in New York City, a position from which she stepped down in January 2023. She continues to serve on the faculty of MSK; she holds the C

    2/27/24 9:05:00 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    $ICAD
    Financials

    Live finance-specific insights

    View All

    RadNet's Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

    Acquisition contributes iCAD's commercial, technology, and regulatory capabilitiesThe acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutionsThe combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ:ICAD) ("iCAD"), a global lead

    7/17/25 9:00:00 AM ET
    $ICAD
    $RDNT
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    iCAD Reports Financial Results for First Quarter Ended March 31, 2025

    NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin of 86%92 Total deals closed in Q1, 19 of which were ProFound Cloud Dana Brown, President and CEO of iCAD commented, "We saw meaningful progress this quarter with increasing a

    5/13/25 4:01:00 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer

    The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancerThe transaction is expected to add to RadNet's wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countriesWith iCAD's seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate RadNet's growth and leadership in cancer screening and artificial intelligenceFollowing the completion of the acquisition, iCAD will be integrated into RadNet's DeepHealth portfolio of solutionsRadNet will host a conference call and

    4/15/25 4:01:37 PM ET
    $ICAD
    $RDNT
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    $ICAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by iCAD Inc. (Amendment)

    SC 13G/A - ICAD INC (0000749660) (Subject)

    2/14/24 9:00:29 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by iCAD Inc. (Amendment)

    SC 13G/A - ICAD INC (0000749660) (Subject)

    7/24/23 3:59:05 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by iCAD Inc.

    SC 13G - ICAD INC (0000749660) (Subject)

    3/15/23 3:15:23 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care